LONDON - Inion Group became the first Finnish company to have an initial public offering on the main market in London, grossing £33 million (US$62.5 million) to develop its bone-generating polymer, and underlining London's status as the only market in Europe that is receptive to small biotechnology companies. (BioWorld International)
LONDON - Cambridge Antibody Technology Group plc committed its future to a five-year deal with AstraZeneca plc, in which the partners will invest $175 million to fund 25 antibody discovery programs and AstraZeneca will pay £75 million (US$139.1 million) to become CAT's largest shareholder at 19.9 percent. (BioWorld Today)
LONDON - Cambridge Antibody Technology Group plc committed its future to a five-year deal with AstraZeneca plc, in which the partners will invest $175 million to fund 25 antibody discovery programs and AstraZeneca will pay £75 million (US$139.1 million) to become CAT's largest shareholder at 19.9 percent. (BioWorld Today)
LONDON - Cambridge Antibody Technology Group plc has begun to wind down expenditure on Trabio, the first antibody it has developed in-house, after the product failed to meet its primary endpoint in a European Phase II/III pivotal trial. (BioWorld International)
